Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey
This article was originally published in PharmAsia News
Executive Summary
Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth
You may also be interested in...
Priming Russia’s Pharma Industry For Innovation
The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.
Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention
TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business
Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention
TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business